ArticleTheranostics2019

New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.

Maeva Dufies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.